deltatrials
Terminated PHASE1 INTERVENTIONAL 7-arm NCT05252390

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Sponsor: Nuvation Bio Inc.

Conditions Advanced Solid Tumor Breast Cancer Breast Carcinoma Breast Tumor Cancer of Breast Cancer of Ovary Cancer of Pancreas Cancer of Prostate Cancer of the Breast Cancer of the Ovary Cancer of the Pancreas Cancer of the Prostate Castrate Resistant Prostate Cancer Castration Resistant Prostatic Cancer Castration Resistant Prostatic Neoplasms Ovarian Cancer Ovary Cancer Ovary Neoplasm Pancreas Cancer Pancreas Neoplasm Pancreatic Cancer Prostate Cancer Prostate Neoplasm Prostatic Cancer Triple Negative Breast Cancer Triple Negative Breast Neoplasms Triple-negative Breast Cancer
Interventions Enzalutamide NUV-868 Olaparib
Updated 23 times since 2022 Last updated: Nov 4, 2025 Started: Mar 29, 2022 Primary completion: Jul 15, 2024 Completion: Jul 15, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The Sponsor has achieved its objectives.

Other terminated trials from Nuvation Bio Inc.

More terminations from Nuvation Bio Inc.

Other Advanced Solid Tumor trials with similar outcome

Browse all Advanced Solid Tumor trials

Listed as NCT05252390, this PHASE1 trial focuses on Advanced Solid Tumor and Breast Cancer and remains terminated or withdrawn. Sponsored by Nuvation Bio Inc., it has been updated 23 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~May 2023 · 3 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Nov 2023 · 3 months · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jun 2024 · 3 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Apr 2025 · 5 months · monthly snapshot~Apr 2025 – ~Dec 2025 · 8 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

23 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE1

    Phase: PHASE1/PHASE2 → PHASE1

  2. Apr 2025 — Dec 2025 [monthly]

    Terminated PHASE1/PHASE2

    Status: Recruiting → Terminated

  3. Nov 2024 — Apr 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1/PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 18 earlier versions

  1. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  2. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Mar 2024 — Jun 2024 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jan 2024 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Nov 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

  6. Aug 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  10. Feb 2023 — May 2023 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

  12. Nov 2022 — Jan 2023 [monthly]

    Recruiting PHASE1_PHASE2

  13. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  15. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  16. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  17. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  18. Mar 2022 — Apr 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Nuvation Bio Inc.
Data source: Nuvation Bio Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Baltimore, United States , Boston, United States , Dallas, United States , Detroit, United States , Fairfax, United States , Fort Worth, United States , Huntersville, United States , Lone Tree, United States , Los Angeles, United States and 11 more locations